| scholarly article | Q13442814 |
| P50 | author | James W Jacobberger | Q60656052 |
| Tomas Radivoyevitch | Q52352675 | ||
| P2093 | author name string | John Pink | |
| Song-Mao Chiu | |||
| Tammy Stefan | |||
| Timothy J. Kinsella | |||
| Charles A. Kunos | |||
| P2860 | cites work | p53 sends nucleotides to repair DNA. | Q53412450 |
| R: A Language for Data Analysis and Graphics | Q56268347 | ||
| Cell cycle-dependent expression of mammalian ribonucleotide reductase. Differential regulation of the two subunits | Q69900353 | ||
| Cell cycle-dependent regulation of mammalian ribonucleotide reductase. The S phase-correlated increase in subunit M2 is regulated by de novo protein synthesis | Q72393641 | ||
| Concurrent cisplatin-based radiotherapy and chemotherapy for locally advanced cervical cancer | Q77321076 | ||
| A ribonucleotide reductase gene involved in a p53-dependent cell-cycle checkpoint for DNA damage | Q28138556 | ||
| Wild-type p53 regulates human ribonucleotide reductase by protein-protein interaction with p53R2 as well as hRRM2 subunits | Q28180311 | ||
| The human ribonucleotide reductase subunit hRRM2 complements p53R2 in response to UV-induced DNA repair in cells with mutant p53 | Q28212918 | ||
| Cell-cycle checkpoints and cancer | Q28293996 | ||
| Structure and function of the radical enzyme ribonucleotide reductase | Q28619961 | ||
| Structure, function, and mechanism of ribonucleotide reductases | Q30164061 | ||
| Modulating radiation resistance by inhibiting ribonucleotide reductase in cancers with virally or mutationally silenced p53 protein | Q33638420 | ||
| Phase I trial of pelvic radiation, weekly cisplatin, and 3-aminopyridine-2-carboxaldehyde thiosemicarbazone (3-AP, NSC #663249) for locally advanced cervical cancer | Q33658330 | ||
| Ribonucleotide reductase M1 subunit in cellular proliferation, quiescence, and differentiation. | Q34163730 | ||
| p53 point mutation in HPV negative human cervical carcinoma cell lines | Q38335537 | ||
| Kinetics of H2AX phosphorylation after exposure to cisplatin | Q39947163 | ||
| Phosphorylation of histone H2AX as a measure of radiosensitivity | Q40594249 | ||
| Overexpression of the R2 subunit of ribonucleotide reductase in human nasopharyngeal cancer cells reduces radiosensitivity | Q40635744 | ||
| Expression of ribonucleotide reductase after ionizing radiation in human cervical carcinoma cells. | Q41038705 | ||
| Global Comparison of Radiation and Chemotherapy Dose-Response Curves with a Test for Interaction | Q41540078 | ||
| Regulation of mammalian ribonucleotide reduction and dNTP pools after DNA damage and in resting cells | Q42489935 | ||
| Tumor antigen and human chorionic gonadotropin in CaSki cells: a new epidermoid cervical cancer cell line | Q42802859 | ||
| Controlled protein degradation regulates ribonucleotide reductase activity in proliferating mammalian cells during the normal cell cycle and in response to DNA damage and replication blocks | Q42803744 | ||
| Deoxyribonucleoside kinases: two enzyme families catalyze the same reaction | Q46492978 | ||
| P433 | issue | 5 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | cervix uterine cancer | Q160105 |
| P304 | page(s) | 574-581 | |
| P577 | publication date | 2010-09-10 | |
| P1433 | published in | Radiation Research | Q2446628 |
| P1476 | title | Ribonucleotide reductase inhibition enhances chemoradiosensitivity of human cervical cancers | |
| Ribonucleotide Reductase Inhibition Enhances Chemoradiosensitivity of Human Cervical Cancers | |||
| P478 | volume | 174 |
| Q36335873 | A dose escalation and pharmacodynamic study of triapine and radiation in patients with locally advanced pancreas cancer |
| Q35782691 | A phase I and pharmacokinetic study of oral 3-aminopyridine-2-carboxaldehyde thiosemicarbazone (3-AP, NSC #663249) in the treatment of advanced-stage solid cancers: a California Cancer Consortium Study. |
| Q33419816 | A phase I-II evaluation of veliparib (NSC #737664), topotecan, and filgrastim or pegfilgrastim in the treatment of persistent or recurrent carcinoma of the uterine cervix: an NRG Oncology/Gynecologic Oncology Group study |
| Q34015533 | Deoxycytidine kinase augments ATM-Mediated DNA repair and contributes to radiation resistance |
| Q35318609 | Deoxynucleoside salvage facilitates DNA repair during ribonucleotide reductase blockade in human cervical cancers |
| Q35560319 | Determination of triapine, a ribonucleotide reductase inhibitor, in human plasma by liquid chromatography tandem mass spectrometry |
| Q50223215 | Editorial: New Approaches to Radiation-Therapeutic Agent Cancer Care for Women |
| Q36347370 | Elevated ribonucleotide reductase levels associate with suppressed radiochemotherapy response in human cervical cancers |
| Q38005222 | Emerging drugs for cervical cancer. |
| Q38314157 | Emerging drugs for the treatment of cervical cancer |
| Q37360356 | Gemcitabine and carboplatin demonstrate synergistic cytotoxicity in cervical cancer cells by inhibiting DNA synthesis and increasing cell apoptosis |
| Q36656132 | Inhibition of Poly(ADP-Ribose) Polymerase Enhances Radiochemosensitivity in Cancers Proficient in DNA Double-Strand Break Repair |
| Q39168925 | Investigational drugs for the treatment of cervical cancer. |
| Q33944113 | Long-Term Disease Control with Triapine-Based Radiochemotherapy for Patients with Stage IB2-IIIB Cervical Cancer |
| Q36170870 | Mammalian ribonucleotide reductase subunit p53R2 is required for mitochondrial DNA replication and DNA repair in quiescent cells |
| Q35796011 | Management of 3-aminopyridine-2-carboxaldehyde thiosemicarbazone-induced methemoglobinemia. |
| Q34482362 | Molecular Strategies of Deoxynucleotide Triphosphate Supply Inhibition Used in the Treatment of Gynecologic Malignancies |
| Q33441115 | Phase I Trial of Triapine-Cisplatin-Paclitaxel Chemotherapy for Advanced Stage or Metastatic Solid Tumor Cancers |
| Q33437008 | Phase I trial of daily triapine in combination with cisplatin chemotherapy for advanced-stage malignancies |
| Q34662652 | Radiochemotherapy plus 3-aminopyridine-2-carboxaldehyde thiosemicarbazone (3-AP, NSC #663249) in advanced-stage cervical and vaginal cancers |
| Q91813335 | Radiopharmaceuticals for Persistent or Recurrent Uterine Cervix Cancer |
| Q35056458 | Radiosensitization of human cervical cancer cells by inhibiting ribonucleotide reductase: enhanced radiation response at low-dose rates |
| Q36868936 | Ribonucleotide reductase expression in cervical cancer: a radiation therapy oncology group translational science analysis |
| Q36112585 | Ribonucleotide reductase inhibition restores platinum-sensitivity in platinum-resistant ovarian cancer: a Gynecologic Oncology Group Study. |
| Q35971759 | Ribonucleotide reductase inhibitors: a new look at an old target for radiosensitization |
| Q36406993 | Targeting HGF/c-MET induces cell cycle arrest, DNA damage, and apoptosis for primary effusion lymphoma |
| Q38148222 | Targeting ribonucleotide reductase for cancer therapy. |
| Q36353167 | Targeting the Large Subunit of Human Ribonucleotide Reductase for Cancer Chemotherapy. |
| Q36195902 | Therapeutic Mechanisms of Treatment in Cervical and Vaginal Cancer. |
| Q55016411 | Triapine Radiochemotherapy in Advanced Stage Cervical Cancer. |
Search more.